Find Funding Opportunities

The Office of Disease Prevention (ODP) and participating National Institutes of Health (NIH) Institutes, Centers, and Offices (ICs) are issuing this Notice of Special Interest (NOSI) to solicit applications proposing to strengthen the evidence base for preventive screening services where the evidence is lacking, of poor quality, conflicting, or the balance of benefits and harms cannot be determined. This NOSI encourages the development and use of innovative and rigorous methods and approaches to close high priority evidence gaps to elevate screening services to a level suitable for a definitive grade or recommendation. The specific research interests of participating NIH ICs are detailed within.

The purpose of this Notice of Special Interest (NOSI) is to encourage the development and validation of animal models that recapitulate the phenotypic and physiologic characteristics of a defined pain type/indication and/or disease-associated pain condition and endpoints or outcome measures that can be used therein. The goal of this NOSI is to promote a significant improvement in the translational relevance of animal models and/or outcome measures that will be utilized to facilitate future development of non-addictive analgesics. Ideally, models or measures proposed for this NOSI would have the potential to provide feasible and meaningful assessments of efficacy following therapeutic intervention that would be applicable in both preclinical and clinical settings.

This Notice of Special Interest is a reissue of NOT-MD-19-001 Notice of Special Interest in Research on the Health of Sexual and Gender Minority (SGM) Populations. The reissue includes updates of programmatic interest for NHGRI, NIA, NIDCR, NIDDK, and ORWH, and updated Scientific Contacts.

This Funding Opportunity Announcement (FOA) solicits applications for the early-stage development of therapeutics to mitigate the adverse health effects resulting from toxic chemical exposure. Chemical threats are toxic compounds that could be used in a terrorist attack or accidentally released from industrial production, storage or shipping. They include specific chemical warfare agents, toxic industrial chemicals, pesticides, and pharmaceutical-based agents. The overall scope of this solicitation includes validation of therapeutic targets and preclinical characterization of lead compounds. The UG3 phase of this FOA supports target validation and characterization of initial lead compound(s); UH3 phase activities include candidate optimization and in vivo demonstration of activity and efficacy in relevant post-exposure models. At the conclusion of the overall UG3/UH3 funding period, projects are expected to deliver at least one well-characterized therapeutic candidate.

This Funding Opportunity Announcement (FOA) invites applications to the National Institute on Aging's (NIA) Small Business Innovation Research (SBIR) program. The aim of this FOA is to support research that may lead to the development of innovative products and/or services that have the potential to advance progress in preventing and treating Alzheimer's disease (AD) and AD-related dementias (ADRD) and/or caring for and treating patients living with AD/ADRD.

This Funding Opportunity Announcement (FOA) invites applications to the National Institute on Aging's (NIA) Small Business Technology Transfer Research (STTR) program. The aim of this FOA is to support research that may lead to the development of innovative products and/or services with the potential to advance progress in preventing and treating Alzheimer's disease (AD) and AD-related dementias (ADRD) and/or caring for and treating patients living with AD/ADRD.

The purpose of this NOSI is to solicit projects on preventive interventions that address cardiometabolic risk factors in populations that experience health disparities.

This Funding Opportunity Announcement (FOA) solicits R01 grant applications that propose independent research projects that are within the scientific mission areas of the ?participating NIH Institutes or Centers. This program is intended to support New Investigators and At-Risk Investigators from diverse backgrounds, including those from groups underrepresented in the health-related sciences.Investigators from diverse backgrounds, including those from underrepresented groups (e.g., see NOT-OD-20-031, Notice of NIHs Interest in Diversity), are eligible to apply. Investigators from categories A and B are particularly encouraged to work with their institutions to apply

The NIH INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Project seeks to improve health and quality-of-life for individuals with Down syndrome (DS). This Notice of Special Interest (NOSI) announces NIH support for administrative supplement applications for actively funded projects to meet NIH Down syndrome research objectives related to the NIH INCLUDE Project as listed below.

The National Institute of Environmental Health Science (NIEHS), in partnership with Fogarty International Center (FIC), National Institute of Minority Health and Health Disparities (NIMHD), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Mental Health (NIMH), National Institute of Nursing Research (NINR), National Heart Blood and Lung Institute (NHBLI) and National Institute of Allergy and Infectious Disease (NIAID) is leading an NIH-wide Climate Change and Health Initiative (CCHI) with the goals of: reducing the health threats posed by climate change across the lifespan; improving the health of people who are at increased risk from or disparately affected by climate change impacts; and building health resilience among individuals, communities, nations around the world, thereby increasing health equity. As a part of this CCHI, this NOSI encourages applications that address the impact of climate change on health and well-being over the life course, including the health implications of climate change in the United States and globally.